Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.
Precirix has raised $88.2M in total funding. The most recent round was Series B. The last funding was announced in March 2022.
Precirix's investors include Novo Holdings, Jeito Capital, Inkef, HealthCap, Forbion Capital Partners.
Precirix is headquartered in Brussels, Belgium.
Precirix is a platform that is developing radio-immunotherapeutic drugs for cancer patients.
Precirix is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Precirix — Funding & Investors." VCBacked, March 16, 2022, https://www.vcbacked.co/company/precirix. Accessed November 13, 2026.
VCBacked. (2022). Precirix — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/precirix
{{cite web |title=Precirix — Funding & Investors |url=https://www.vcbacked.co/company/precirix |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Precirix? Request a listing update